Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety of Prevenar 13 in Chinese infants using Ningbo EHR
CTR20180543Phase 4Completed
- Sponsor
- Pfizer
- Start
- Apr 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, Pneumococcal pneumonia (PP), pneumococcal meningitis, pneumococcal septicemia, pneumococcal bacteremia, sponsored by Pfizer. Started Apr 2018; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal diseasePneumococcal pneumonia (PP)pneumococcal meningitispneumococcal septicemiapneumococcal bacteremia
Beyond the preview
Go deeper on CTR20180543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180543.